We have also ventured into the delivery of large molecules in recent years with our ophthalmology product, prolonging the administration frequency from once-a-month to once every 4-6 months, and this sustained release technology platform can be used in both small and large molecules.

How does the company plan to penetrate the market?

TLC has different strategies for different markets. The US and European territories are more suited for introducing NCEs, while Asia Pacific markets are more suited for the penetration of generic or new formulation products. TLC's different product lines can help fulfill the needs of the different territories, respectively.

Tell us about your businesses in Asia Pacific?

We have already launched an oncology product, Lipo-Dox, in Taiwan since 2002; and partnered with the biggest pharmacy chain in Japan and one of the top five pharmas in Korea for our super generic product ProFlow, and we're currently in the final stage of negotiation for the out-licensing of the distribution rights of ProFlow for the Greater China territory.